PMM2P2

Across TCGA pan-cancer cohorts, PMM2P2 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated PMM2P2 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PMM2P2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PMM2P2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LIHC, CHOL, and BLCA are the cancer types where PMM2P2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	III,IV	0.119	0.662	<.001	57	view →
CHOL	DFS	Tertile	All	0.045	0.486	.009	45	view →
BLCA	OS	Tertile	All	0.491	0.625	.016	36	view →
KIRC	DFS	Tertile	III,IV	0.141	0.499	<.001	30	view →
LUAD	OS	Tertile	All	0.908	0.799	.028	30	view →
STAD	DFS	Median	II,III,IV	0.512	0.688	.003	27	view →
LUSC	DFS	Median	IV	0.134	0.827	.014	26	view →
HNSC	OS	Tertile	IV	0.756	0.597	.020	24	view →
DLBC	DFS	Quartile	All	0.119	0.697	.004	20	view →
PAAD	DFS	Tertile	III,IV	0.118	0.734	.014	18	view →
ACC	DFS	Tertile	III,IV	0.048	0.457	.015	18	view →
ESCA	OS	Median	All	0.756	0.634	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

PMM2P2–LIHC (OS)

Open the LIHC breakdown →